NCT05343572View on ClinicalTrials.gov

Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Asherman SyndromeAtrophic EndometriumRecurrent Implantation Failure
Interventions
DRUG

Plerixafor

A 20mg single dose of PLERIXAFOR is administered subcutaneously the evening prior to scheduled standard of care surgery for women with AS, AE or RIF for peripheral mobilization of stem cells. For subjects weighing \>83 kilogram, the dosing is a single dose of 0.24 milligram per kilogram.

Trial Locations (1)

06477

RECRUITING

Yale Fertility Center, Orange

All Listed Sponsors
lead

Hugh Taylor

OTHER